Illumina Reaffirms Annual Revenue Forecast Over Continued Sluggish Demand

Reuters05-03

May 2 (Reuters) - Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.

The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers.

The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%.

The company said it is on track to divest cancer diagnostic test maker Grail and expects to finalize terms by the second quarter.

U.S. life sciences Illumina's first-quarter revenue was $1.08 billion, above analysts' estimate of $1.05 billion.

On an adjusted basis, it earned profit of 9 cents per share in the quarter ended March 31, narrowly beating analysts' average estimate of 4 cents per share.

Shares of the company fell to 2.5% at $120.9 in aftermarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

2

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432635289?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-03 07:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432635289","market":"us","top_or_hot":-1,"title":"Illumina Reaffirms Annual Revenue Forecast Over Continued Sluggish Demand","media":"Reuters","content":"<html><head></head><body><p>May 2 (Reuters) - Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.</p><p>The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers.</p><p>The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%.</p><p>The company said it is on track to divest cancer diagnostic test maker Grail and expects to finalize terms by the second quarter.</p><p>U.S. life sciences Illumina&#39;s first-quarter revenue was $1.08 billion, above analysts&#39; estimate of $1.05 billion.</p><p>On an adjusted basis, it earned profit of 9 cents per share in the quarter ended March 31, narrowly beating analysts&#39; average estimate of 4 cents per share.</p><p>Shares of the company fell to 2.5% at $120.9 in aftermarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/93dff6982a55ca1ed3335c61e42089a1\" tg-width=\"842\" tg-height=\"622\"/></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Reaffirms Annual Revenue Forecast Over Continued Sluggish Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Reaffirms Annual Revenue Forecast Over Continued Sluggish Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 07:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 2 (Reuters) - Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.The San Diego, California-...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2432635289","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432635289","pubTimestamp":1714692252,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 2  - Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers.The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this ye","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"Illumina重申需求持续低迷的年度收入预测","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"May 2 (Reuters) - Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.The San Diego, California-based company, whose tools and services are used in developing therapies and vaccines, has seen both a slowdown in demand from key markets such as China and cautious spending from its customers.The gene sequencing machine maker continues to expect revenue growth from its core segment to be roughly flat this year compared with 2023, and still sees its adjusted operating margin to be about 20%.The company said it is on track to divest cancer diagnostic test maker Grail and expects to finalize terms by the second quarter.U.S. life sciences Illumina's first-quarter revenue was $1.08 billion, above analysts' estimate of $1.05 billion.On an adjusted basis, it earned profit of 9 cents per share in the quarter ended March 31, narrowly beating analysts' average estimate of 4 cents per share.Shares of the company fell to 2.5% at $120.9 in aftermarket trading.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432635289"}